drugset / Trial / NCT04619082
TAF to Prevent HBV Reactivation in Cancer Patients
Phase 4
Active not recruiting
102 enrolled
Chiayi Christian Hospital
Chi Mei Medical Hospital · collabDalin Tzu Chi General Hospital · collabNational Taiwan University Hospital, Yun-Lin Branch · collabSt. Martin De Porress Hospital · collab
NaSingle-groupOpen-labelPrevention
Summary
Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive cancer patients receiving chemotherapy.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tenofovir alafenamide | Small molecule | 25 mg | — |